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ABSTRACT
Introduction: American Diabetes Association
consensus guidelines emphasize individualized
treatment in the management of type 2 diabetes
mellitus (T2DM). Early glycemic response is a
clinical marker that may predict longer term
efficacy for individual patients and provide a
clinical tool to enhance personalized treatment.
This analysis evaluated whether glycemic
response measured at week 12 (‘‘early’’) could
serve as a reliable predictor of glycemic control
at weeks 24 and 52 of therapy in patients with
T2DM.
Methods: We used data from 3 randomized,
controlled clinical trials that evaluated patients
with T2DM treated with 3 commonly prescribed
glucose-lowering medications: metformin
(n = 597), sulfonylurea (n = 626), and insulin
glargine (n = 1046). The gradient boosting
method was used to identify predictors of
subsequent response; predictive accuracy was
represented by sensitivity, specificity, positive
predictive value (PPV), and negative predictive
value (NPV). Treatment success at weeks 24 and
52 was assessed for each patient and defined as
achieving a glycated hemoglobin (HbA1c) level
of\7.0% or a reduction from baseline of C1.0%.
Results: The predictive parameters (sensitivity,
specificity, PPV, and NPV) for improvements in
HbA1c at week 24 for metformin were 0.83, 0.81,
0.44, and 0.96; for sulfonylurea, 0.79, 0.94,
0.71, and 0.96; and for insulin glargine, 0.67,
0.89, 0.65, and 0.90. The predictive parameters
for improvements in HbA1c at week 52 for
metformin were 0.73, 0.84, 0.56, and 0.92 and
for sulfonylurea, 0.45, 0.94, 0.74, and 0.82.
Conclusion: High predictive values identified
in this analysis support ‘‘early’’ response as an
appropriate tool for predicting treatment
success at weeks 24 and 52. The high NPV
(lack of early glycemic response) appears to be
an effective indicator of the likely need for
change in (or intensification of) therapy. These
data support the current guideline
recommendations that clinicians evaluate
therapeutic responses to pharmacologic
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interventions with metformin, sulfonylureas, or
insulin glargine as early as week 12.
Keywords: Early response; Glycemic control;
Gradient boosting; Insulin glargine; Metformin;
Predictive values; Sulfonylurea; Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM) has become a
global epidemic. The prevalence of diabetes in
2013 was 382 million people and is expected to
increase to 592 million people by the year 2035
[1]. While a myriad of glucose-lowering
therapies are available, many patients with
T2DM still do not reach treatment goals [2–4],
exposing them to the risk of debilitating and
costly complications. Joint guidelines from the
American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD) recommend a patient-centered,
personalized approach for the treatment of
diabetes, tailored to patients’ individual needs
and preferences along with considerations that
include age, weight, comorbidities and
complications, patient attitude, risk of
hypoglycemia, disease duration, life
expectancy, and available resources [5].
Reliable, affordable, and convenient early
markers used commonly in clinical practice
and demonstrated to be predictive of long-
term results may facilitate a personalized
approach to therapy.
Early response to medication has been
demonstrated to be a robust predictor of
subsequent response to the medication across
multiple therapeutic areas; in particular, lack of
early response predicts lack of subsequent
response. This early-response phenomenon has
been observed in the treatment of
schizophrenia with antipsychotics [6–10],
bipolar disorder with antidepressants [11],
major depressive disorder with antidepressants
[12], attention-deficit/hyperactivity disorder
with a selective norepinephrine reuptake
inhibitor [13, 14], plaque psoriasis with
monoclonal antibody therapy [15],
rheumatoid arthritis with monoclonal
antibody therapy [16], and breast cancer with
neoadjuvant chemotherapy [17]. Little is
known about this early-response phenomenon
in the treatment of diabetes. Accurate
predictions of response to medication have
notable implications for clinical
improvements, treatment choices or
transitions, and healthcare costs by helping
clinicians make early treatment decisions for
patients who are unlikely to be responsive to
their current therapies and minimizing the time
patients spend on suboptimal treatment
regimens [18–22].
In T2DM, Karl et al. [23] demonstrated that
6-month glycemic responses to insulin glargine
can be predicted after 6–12 weeks of therapy—
specifically, fasting plasma glucose[180.2 mg/
dL (10 mmol/L) after 6–12 weeks of insulin
glargine therapy indicated that reaching a
glycated hemoglobin (HbA1c) level target of
B7.0% was unlikely—and thereby provided a
means for predicting response to therapy early
in the treatment approach; however, the
predictive accuracy of this method was
unclear. Given the limited understanding of
early glycemic response to glucose-lowering
medication, it is currently unclear whether
early response to glucose-lowering medication
is a robust predictor of subsequent response.
To help address this important information
gap, this analysis assessed the predictive power
of early response for subsequent response across
3 commonly prescribed glucose-lowering
medications: metformin, sulfonylurea, and
insulin glargine. We hypothesized that
glycemic response at week 12 (early response)
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predicts subsequent glycemic responses at week
24 (the primary outcome) and week 52 (the




To evaluate the hypothesis for the 3 commonly
prescribed glucose-lowering medications of
metformin, sulfonylurea, and insulin glargine,
3 previously published, randomized clinical
trials that included large samples with
individual patient data were used for this
study (Table 1).
Metformin data (n = 597) were obtained
from a trial that compared the glycemic
control of metformin and pioglitazone in 1199
randomized, glucose-lowering drug-naive
patients with poorly controlled T2DM over
52 weeks [24].
Sulfonylurea data (n = 626) were obtained
from a trial that compared the glycemic control
of the sulfonylurea gliclazide and the
thiazolidinedione pioglitazone in 1270
randomized, drug-naive patients with poorly
controlled T2DM over 52 weeks [25].
Insulin glargine data (n = 1046) were
obtained from a trial that compared the
durability of glycemic control of once-daily
insulin glargine and twice-daily insulin lispro
during a 6-month initiation phase in 2091
randomized patients with T2DM on oral
glucose-lowering medications [26]. Patients
with HbA1c levels of B7.0% at the end of the
initiation phase continued in a maintenance
phase for up to 24 months. Because only
selected patients were monitored during the
24-month maintenance phase, the trial design
did not permit 52-week follow-up for insulin
glargine data in the current analysis.
Glycemic control for each of the 3 trials is
shown in Table 2. Data from patients with non-
missing HbA1c level values at baseline and
weeks 12, 24, and 52 from the aforementioned
clinical trials were analyzed. Treatment success
at week 24 (the primary outcome) and week 52
(the secondary outcome) was assessed for each
patient and defined as an HbA1c level reduction
Table 1 Randomized clinical trials from which data were pooled for this analysis











SUa vs. pio 1270 626 16-week titration
36-week maintenance




If HbA1c B7.0%, then 24-month
maintenance
Glargine insulin glargine, Lispro insulin lispro, Met metformin, OAD oral anti-hyperglycemic medication, Pio pioglitazone,
SU sulfonylurea, HbA1c glycated hemoglobin
a Treatment arm included in present analysis
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of C1.0% or an HbA1c level of\7.0%. Thus, a
patient needed to meet 1 of the 2 success criteria
by reaching either an HbA1c reduction of C1.0%
or an HbA1c level of \7.0% to be considered
having achieved treatment success.
The use of an HbA1c level reduction of C1.0%
as the threshold value in this analysis was
selected because of its clinical relevance in
diabetes management. The UK Prospective
Diabetes Study showed that every 1.0%
reduction in mean HbA1c level was associated
with reductions of 21% for any diabetes-related
endpoint, 21% for diabetes-related deaths, 14%
for myocardial infarctions, and 37% for
microvascular complications [27]. Further, the
National Institute for Health and Care
Excellence guideline selected an HbA1c level
reduction of C1.0% with the use of glucagon-
like peptide-1 receptor agonists as a threshold
criterion for continuing therapy [28, 29]. The
use of an HbA1c level of \7.0% was selected
because it is consistent with the ADA
recommended HbA1c target value [30].
Gradient Boosting Method
The gradient boosting method was applied to
the dataset from each trial to identify the
optimal early-response variable, defined as the
variable with the largest relative inference
among the candidate variables for subsequent
response prediction [31]. Candidate early-
response variables were based on HbA1c levels
at week 12 of\7.4%,\7.3%,\7.2%, …,\6.6%;
Table 2 Glycemic control
Measure Time point Met (N5 597) SU (N5 626) Glargine (N5 1046)
HbA1c (%) Baseline 8.7 (1.0) 8.7 (1.1) 8.9 (1.3)
Week 12 7.5 (1.1) 7.2 (1.1) 7.6 (1.1)
Week 24 7.1 (1.0) 7.0 (1.1) 7.4 (1.2)
Week 52 7.2 (1.1) 7.3 (1.2) NA
HbA1c change
a (%) Week 12 -1.1 (1.0) -1.5 (1.0) -1.4 (1.2)
Week 24 -1.6 (1.2) -1.7 (1.1) -1.5 (1.3)
Week 52 -1.5 (1.2) -1.3 (1.1) NA
FBG (mmol/L) Baseline 11.3 (2.8) 11.2 (2.9) 10.1 (4.0)
Week 12 9.0 (2.4) 8.5 (2.4) 7.2 (3.0)
Week 24 8.7 (2.3) 8.4 (2.4) 7.0 (2.7)
Week 52 9.1 (2.5) 9.3 (3.0) NA
FBG changea (mmol/L) Week 12 -2.2 (2.5) -2.7 (2.7) -2.9 (3.5)
Week 24 -2.5 (2.7) -2.8 (2.8) -3.2 (3.7)
Week 52 -2.1 (2.9) -2.0 (2.9) NA
Mean (standard deviation) shown
FBG fasting blood glucose measure, Glargine insulin glargine, Met metformin, NA not applicable, SU sulfonylurea, HbA1c
glycated hemoglobin
a Change from baseline
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a reduction in HbA1c level of C1.3%, C1.2%,
C1.1%, …, C0.5%; fasting blood glucose (FBG)
levels at week 12 of \12.5, \12.0, \11.5, …,
\8.5 mmol/L; and a reduction in FBG level of
C4.5, C4.0, C3.5, …, C0.5 mmol/L.
Predictive parameters included sensitivity,
which is the percentage of subsequent
responders correctly identified; specificity, the
percentage of subsequent non-responders
correctly identified; positive predictive value
(PPV), the percentage of subsequent responders
among early responders; and negative
predictive value (NPV), the percentage of
subsequent non-responders among early non-
responders (Table 3).
Correlation Coefficients
Correlation coefficients for HbA1c level and
HbA1c level change were assessed using the
Pearson product-moment correlation method
[32]. The analysis was conducted in SAS 9.0 (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Patient Disposition and Demographics
Data from 2269 patients were included in this
analysis (Table 1). For metformin, sulfonylurea,
and insulin glargine, 79%, 83%, and 85% of
patients with available HbA1c data at baseline
were assessed at week 12 and week 24 (Table 4).
For metformin and sulfonylurea, 72% and 75%
of patients also had HbA1c assessed at week 52.
Across studies, the mean age was 56 or
57 years, the mean body weight was 88 or
90 kg, the mean body mass index was 31 or
32 kg/m2, and the mean HbA1c level was 8.7%
or 9.0% (Table 4). The percentage of male
patients ranged from 53% to 62%, and the
mean FBG level ranged from 10.9 to 11.3 mmol/
L. The mean duration of diabetes was 3.0 years
for patients treated with metformin and
sulfonylurea and 9.3 years for patients treated
with insulin glargine.
Predictive Parameters
The optimal early-response variables identified
by the GBM for metformin were a reduction in
HbA1c level of C0.8% at week 24 and a
reduction in HbA1c level of C0.6% at week 52.
The optimal early-response variable for
sulfonylurea was a reduction in HbA1c level of
C1.0% at both week 24 and week 52, and that
for insulin glargine was a reduction in HbA1c
level of C1.0% at week 24. Thus, for each
medication, the optimal early-response
variable was equal or close to a reduction in
HbA1c level of C1.0%, which is considered to be
clinically meaningful. Therefore, we chose a
single, unified early-response measure (a
reduction in HbA1c level of C1.0%) for all 3
medications.








True positive False positivea
No C D
False negativeb True negative
Positive predictive value (PPV) = A/(A ? B)
Negative predictive value (NPV) = D/(C ? D)
a False positive results indicate the speciﬁcity of the
analysis [38]. Few false positive results denote high
speciﬁcity. Speciﬁcity = D/(B ? D)
b False negative results indicate the sensitivity of the
analysis. Few false negative results denote high sensitivity.
Sensitivity = A/(A ? C)
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The GBM did not select an HbA1c level of
\7.0% as an optimal early-response variable in
any case. However, since an HbA1c level of
\7.0% is clinically meaningful, it was
combined with a reduction in HbA1c of C1.0%
for a composite unified measure in assessing
predictive parameters (reduction in HbA1c level
of C1.0% or HbA1c level of\7.0%).
The predictive parameters for improvements
in HbA1c at week 24 and week 52, based on the
composite unified early-response measure
(reduction in HbA1c level of C1.0% or HbA1c
level of\7.0%) for metformin were 0.83, 0.81,
0.44, and 0.96; for sulfonylurea, 0.79, 0.94,
0.71, and 0.96; and for insulin glargine, 0.67,
0.89, 0.65, and 0.90. The predictive parameters
for improvements in HbA1c at week 52 for
metformin were 0.73, 0.84, 0.56, and 0.92 and
for sulfonylurea 0.45, 0.94, 0.74, and 0.82
(Table 5).
The predictive parameters assessed using the
optimal early-response measure and the unified
measure were consistent with those of the
composite unified measure and are shown in
Table 5. Across all therapies and early-response
measures and at both time points, the NPV
remained consistently high (range 0.82–0.98)
(Table 5).
Correlation Coefficients
In the 3 studies, high correlation coefficients
were observed at week 12 vs. week 24 and at
week 12 vs. week 52 for HbA1c level and change
from baseline (Table 6). For HbA1c level, the
ranges for these correlation coefficients were
0.76–0.87 at week 12 vs. week 24 and 0.72–0.73
at week 12 vs. week 52. For HbA1c change, the
ranges were 0.84–0.89 at week 12 vs. week 24
and 0.76–0.80 at week 12 vs. week 52.







Patients with non-missing HbA1c at baseline, week 12,
and week 24
470 (79%) 517 (83%) 886 (85%)
Patients with non-missing HbA1c at baseline, week 12,
week 24, and week 52
432 (72%) 465 (74%) NA
Characteristic
Age (years) 56 ± 9 56 ± 10 57 ± 10
Male (%) 345 (58%) 386 (62%) 552 (53%)
Weight (kg) 90 ± 17 88 ± 17 88 ± 21
BMI (kg/m2) 31 ± 5 31 ± 5 32 ± 6
Duration of diabetes (years) 3.0 ± 3.7 3.0 ± 3.8 9.3 ± 5.9
HbA1c (%) 8.7 ± 1.0 8.7 ± 1.1 9.0 ± 1.2
FBG (mmol/L) 11.3 ± 2.8 11.2 ± 2.9 10.9 ± 3.1
Mean ± standard deviation or n (%) are shown
BMI body mass index, FBG fasting blood glucose, Glargine insulin glargine, Met metformin, SU sulfonylurea, HbA1c
glycated hemoglobin
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DISCUSSION
In this analysis of data from 3 clinical trials
including 3 different glucose-lowering
therapies, we demonstrated that lack of early
glycemic response at week 12 is a reliable
predictor of failure to achieve glycemic
treatment targets (HbA1c \7.0% or HbA1c
reduction of C1.0%) at week 24 and week 52.
NPV is consistently high for all 3 early-response





Agent Sensitivity Speciﬁcity PPV NPV
Composite uniﬁed 24 weeks Met 0.83 0.81 0.44 0.96
SU 0.79 0.94 0.71 0.96
Glargine 0.67 0.89 0.65 0.90
52 weeks Met 0.73 0.84 0.56 0.92
SU 0.45 0.94 0.74 0.82
Uniﬁed 24 weeks Met 0.90 0.74 0.38 0.98
SU 0.85 0.88 0.57 0.97
Glargine 0.74 0.83 0.56 0.92
52 weeks Met 0.82 0.78 0.50 0.94
SU 0.52 0.88 0.62 0.83
Optimal 24 weeks Met 0.82 0.81 0.44 0.96
SU 0.85 0.88 0.57 0.97
Glargine 0.74 0.83 0.56 0.92
52 weeks Met 0.56 0.92 0.67 0.88
SU 0.52 0.88 0.62 0.83
Composite uniﬁed early-response measure: HbA1c reduction of C1.0% or HbA1c level of\7.0% at week 12; uniﬁed early-
response measure: HbA1c reduction of C1.0%; optimal early-response measure: HbA1c reduction of C1.0% for sulfonylurea
and glargine at week 24 and at week 52, HbA1c reduction of C0.8% for metformin at week 24, and HbA1c reduction of
C0.6% for metformin at week 52
Glargine insulin glargine, Met metformin, NPV negative predictive value, PPV positive predictive value, SU sulfonylurea,
HbA1c glycated hemoglobin




HbA1c 12 vs. 24 0.79 0.87 0.76
12 vs. 52 0.72 0.73 NA
HbA1c
change
12 vs. 24 0.85 0.89 0.84
12 vs. 52 0.80 0.76 NA
Glargine insulin glargine, Met metformin, NA not
applicable, SU sulfonylurea, HbA1c glycated hemoglobin
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measures (i.e., unified composite, unified, and
optimal), which indicates that the chances are
82–98% that a patient who lacks early response
to a specific treatment regimen at week 12 will
be unable to achieve treatment targets when
continuing that regimen. The high correlation
coefficients observed at week 12 vs. week 24 and
week 12 vs. week 52 corroborate the
effectiveness of week-12 HbA1c level and its
change from baseline as predictors for long-
term response.
Predicting the lack of early glycemic
response was demonstrated using a clinically
meaningful unified composite measure, which
included a relative (HbA1c reduction of C1.0%)
and an absolute (HbA1c \7.0%) measure of
glycemic control. The choice of a composite
measure may minimize the impact of baseline
HbA1c in predicting treatment responses. For
example, if a patient has a baseline HbA1c level
of 11% and a 24-week HbA1c level of 7.5%, the
patient would be considered a responder
because of the clinically meaningful HbA1c
reduction of 3.5%. Thus, using a composite
measure of response is likely to be applicable
and relevant to more patients than using either
the absolute or the relative measure alone.
Additional information, such as demographic
variables other than HbA1c, may further
improve the NPV or PPV or improve the
applicability of this approach to other or more
specialized patient groups.
Among the prediction parameters
(sensitivity, specificity, PPV, and NPV), NPV
appears to be the most relevant parameter in
clinical practice because clinicians need to
identify patients who do not respond
optimally to current medications or patients
who are unlikely to respond with continued use
of the medications. Clinicians’ early evaluations
may help identify the potential reasons a
patient failed to respond to treatment and rule
out the possibility that lack of response was
driven by poor patient adherence to the
prescribed regimen. Thus, the availability of
such early information may be used as a tool for
clinicians to help identify—shortly after
medication initiation—patients who require a
change in the current medication regimen in
the form of an increased dose, a medication
switch, an augmentation with another
medication, or possibly the discontinuation of
the medication for a period of time to better
evaluate potential underlying causes of the
observed poor response to therapy. The use of
early treatment information may help optimize
patients’ treatment outcomes by minimizing
the duration of suboptimal therapy while
increasing the likelihood of relevant and
timely change in the medication regimen,
which may also help minimize waste of
resources for patients and third-party
healthcare payers alike.
The increasing prevalence of T2DM increases
the economic burden of diabetes care,
highlighting the need for improved methods
of diabetes management. Overall, poor
glycemic control, along with associated
comorbidities, contributes to increased
resource use and costs of diabetes care [22, 33].
Most patients with T2DM do not maintain
glycemic goals in routine clinical practice [2–
4]. Many patients with T2DM may not initiate
or escalate treatment approaches sufficiently
early in the course of the disease to reach
recommended treatment targets [19–21, 34,
35], which contributes to poor glycemic
control and ultimately to increased costs.
Thus, improved methods for early effective
management of T2DM and associated
complications are necessary, including
methods for early treatment decisions.
The ADA and EASD advocate for
personalized, patient-centered treatment of
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T2DM [5]. By design, recommended treatment
paradigms are based on clinical trial results that
involve a highly selected patient population
and an artificial clinical environment [5].
However, personalized care depends on
responsiveness to the needs of individual
patients [36]. Predictive parameters of
glycemic control, particularly NPV, may aid in
personalizing patient therapy by providing a
means of adapting broad, evidence-based
treatment advice to individual therapeutic
responses and promoting appropriate
treatment regimens early in the management
of diabetes.
Current findings need to be evaluated in the
context of this study’s limitations. We relied on
data from randomized, controlled trials. Patient
populations in controlled trials are highly
selected; therefore, real-world results will be
required to replicate the current findings, which
are based on randomized clinical trials. This
study defined treatment response only in terms
of glycemic control, but other important
treatment targets such as weight gain,
hypoglycemia events, and microvascular and
macrovascular complications are also critical in
the management of T2DM. It would be prudent,
therefore, for future research to use a composite
measure that incorporates glycemic control
with other treatment goals. The concept of
threshold-based targets may deviate in part
from the concept of individualized therapy;
therefore, the definition of ‘‘responder’’ in this
analysis may need to be further refined to
include individual patient characteristics. In
addition, although T2DM is a chronic illness,
the current analysis focused on the first 24 and
52 weeks of therapy. Finally, this analysis
focused on early response to 3 common
medications in the treatment of T2DM, and
additional research will be needed to assess the
early-response phenomenon with various
treatment regimens, especially combination
therapy.
The strengths of this study include robust
predictive parameters across a range of
commonly prescribed glucose-lowering
medications. The GBM algorithm is a highly
robust statistical method without parametric
model assumptions [37]. This study used
relatively large sample sizes from randomized
trials, which would help minimize the bias of
known or unknown confounders.
CONCLUSION
The high predictive values identified in this
analysis support that lack of early glycemic
response is a reliable clinical marker for
identifying a lack of treatment success at 24
and 52 weeks. The high NPV (lack of early
glycemic response) appears to be an effective
indicator of the likely need for a change in (or
intensification of) therapy and could become
valuable in clinical practice. Moreover, study
findings support the current treatment
recommendations for T2DM, which advise
clinicians to evaluate therapeutic response to
pharmacologic interventions with metformin,
sulfonylureas, or insulin glargine as early as
12 weeks.
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